Prediction of Prognostic Factors in the Survival of Non-smallcell Lung Cancer Patients with Multiple Brain Metastases
Yıl: 2021 Cilt: 22 Sayı: 1 Sayfa Aralığı: 55 - 60 Metin Dili: İngilizce DOI: 10.4274/imj.galenos.2021.56650 İndeks Tarihi: 29-07-2022
Prediction of Prognostic Factors in the Survival of Non-smallcell Lung Cancer Patients with Multiple Brain Metastases
Öz: Introduction: We aimed to investigate the factors affectingsurvival in non-small-cell lung cancer (NSCLC) patients withmultiple brain metastases.Methods: One hundred thirty patients who were diagnosedwith NSCLC at the time of presentation or during disease followup were evaluated at University of Health Sciences Turkey,İstanbul Training and Research Hospital, Clinic of RadiationOncology between 2012 and 2017.Results: In univariate analysis, significant effects of age >60(p=0.006), stage 4 at the time of diagnosis (p<0.001), KarnofskyPerformance score (KPS) <70 (p<0.001), extracranial metastasispresentation (p=0.014), uncontrolled primary tumor (p=0.002),headache (p=0.037), and recursive partitioning analysis (RPA)Class III (p<0.001) were observed in predicting early mortality.In multivariate Cox regression analysis, stage 3 at the time ofdiagnosis [hazard ratio (HR): 0.419, 95% confidence interval(CI): 0.217-0.809, p=0.010], KPS ≥70 (HR: 14.515, 95% CI: 5.470-38.519, p<0.001), and RPA Class I-II (HR: 0.192, 95% CI: 0.102-0.362, p<0.001) had a positive effect on overall survival.Conclusion: Predicting prognostic factors when makingwhole- brain radiotherapy decisions in NSCLC patients withmultiple brain metastases will help in treating such patientsappropriately. In multiple brain metastases with NSCLCpatients, stage 3 at the time of diagnosis, KPS ≥70, and RPAClass I-II have a positive effect on overall survival.
Anahtar Kelime: Çoklu Beyin Metastazlı Küçük Hücreli Dışı Akciğer Kanserli Hastaların Sağkalımında Prognostik Faktörlerin Öngörülmesi
Öz: Amaç: Çoklu beyin metastazı olan küçük hücreli dışı akciğer kanseri hastalarında sağkalımı etkileyen faktörleri araştırmayı amaçladık. Yöntemler: 2012-2017 yılları arasında Sağlık Bilimleri Üniversitesi, İstanbul Eğitim ve Araştırma Hastanesi, Radyasyon Onkoloji Kliniği’nde, ilk başvuru anında veya hastalığın takibi sırasında beyin metastazı gelişen küçük hücreli dışı akciğer kanseri tanılı 130 hasta değerlendirildi. Bulgular: Tek değişkenli analizde, yaş >60 (p=0,006), tanı anında evre 4 hastalık (p<0,001), Karnofsky Performans skoru (KPS) <70 (p<0,001), ekstrakraniyal metastaz varlığı (p=0,014), primerin kontrol altında olmaması (p=0,002), baş ağrısı (p=0,037) ve RPA sınıfı III (p<0,001) erken mortaliteyi tahmin etmede istatistiksel anlamlı olarak gözlendi. Çok değişkenli Cox regresyon analizinde, ilk başvuru anında evre 3 hastalık (HR: 0,419, 95% CI: 0,217-0,809, p=0,010), 70≥ KPS [hazard ratio (HR): 14,515, 95% CI: 5,470-38,519, p<0,001] ve RPA Sınıf I-II’nin (HR: 0,192, 95% CI: 0,102-0,362, p<0,001) genel sağkalım üzerinde olumlu etkisi vardı. Sonuç: Çoklu beyin metastazı olan küçük hücreli dışı akciğer kanseri hastalarında tüm beyin radyoterapisi kararı verirken prognostik faktörlerin öngörülmesi hastaların uygun şekilde tedavi edilmesine yardımcı olacaktır. İlk başvuru anında evre 3 hastalık, KPS ≥70 ve RPA sınıf I-II çoklu beyin metastazı olan küçük hücreli dışı akciğer kanseri hastalarında genel sağkalımı olumlu yönde etkiler.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394-424.
- 2. Goncalves PH, Peterson SL, Vigneau FD, Shore RD, Quarshie WO, Islam K, et al. Risk of brain metastases in patients with nonmetastatic lung cancer: Analysis of the Metropolitan Detroit Surveillance, Epidemiology, and End Results (SEER) data. Cancer 2016; 122: 1921-7.
- 3. Villarreal-Garza C, de la Mata D, Zavala DG, Macedo-Perez EO, Arrieta O. Aggressive treatment of primary tumor in patients with non-small-cell lung cancer and exclusively brain metastases. Clin Lung Cancer 2013; 14: 6-13.
- 4. Dempke WC, Edvardsen K, Lu S, Reinmuth N, Reck M, Inoue A. Brain Metastases in NSCLC - are TKIs Changing the Treatment Strategy? Anticancer Res 2015; 35: 5797-806.
- 5. Abdallah SM, Wong A. Brain metastases in non-small-cell lung cancer: are tyrosine kinase inhibitors and checkpoint inhibitors now viable options? Curr Oncol 2018; 25(Suppl 1): S103-S14.
- 6. Sahgal A, Soliman H, Larson DA. Whole-brain radiation therapy of brain metastasis. Prog Neurol Surg 2012; 25: 82-95.
- 7. Tsao MN, Lloyd N, Wong RK, Chow E, Rakovitch E, Laperriere N, et al. Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases. Cochrane Database Syst Rev 2012: 2012: CD003869.
- 8. Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997; 37: 745-51.
- 9. Schwartz LH, Litière S, de Vries E, Ford R, Gwyther S, Mandrekar S, et al. RECIST 1.1-Update and clarification: From the RECIST committee. Eur J Cancer 2016; 62: 132-7.
- 10. Stelzer KJ. Epidemiology and prognosis of brain metastases. Surg Neurol Int 2013; 4(Suppl 4): S192-202.
- 11. Dimitropoulos C, Hillas G, Nikolakopoulou S, Kostara I, Sagris K, Vlastos F, et al. Prophylactic cranial irradiation in non-small cell lung cancer patients: who might be the candidates? Cancer Manag Res 2011; 3: 287-94.
- 12. Ji Z, Bi N, Wang J, Hui Z, Xiao Z, Feng Q, et al. Risk factors for brain metastases in locally advanced non-small cell lung cancer with definitive chest radiation. Int J Radiat Oncol Biol Phys 2014; 89: 330‐7.
- 13. Hsiao SH, Chung CL, Chou YT, Lee HL, Lin SE, Liu HE. Identification of subgroup patients with stage IIIB/IV non-small cell lung cancer at higher risk for brain metastases. Lung Cancer 2013; 82: 319-23.
- 14. Rades D, Hansen HC, Schild SE, Janssen S. A New Diagnosis-Specific Survival Score for Patients to be Irradiated for Brain Metastases from Non-small Cell Lung Cancer. Lung 2019; 197: 321-6.
- 15. Bajard A, Westeel V, Dubiez A, Pernet D, Dalphin JC, Depierre A. Multivariate analysis of factors predictive of brain metastases in localised non-small cell lung carcinoma. Lung Cancer 2004; 45: 317‐23.
- 16. Arrieta O, Saavedra‐Perez D, Kuri R, Aviles-Salas A, Martinez L, MendozaPosada D, et al. Brain metastasis development and poor survival associated with carcinoembryonic antigen (CEA) level in advanced non-small cell lung cancer: a prospective analysis. BMC Cancer 2009; 9: 119.
- 17. Sun DS, Hu LK, Cai Y, Li XM, Ye L, Hou HY, et al. A systematic review of risk factors for brain metastases and value of prophylactic cranial irradiation in non-small cell lung cancer. Asian Pac J Cancer Prev 2014; 15: 1233‐9.
- 18. Ding X, Dai H, Hui Z, Ji W, Liang J, Lv J, et al. Risk factors of brain metastases in completely resected pathological stage IIIA-N2 non-small cell lung cancer. Radiat Oncol 2012; 7: 119.
- 19. Jacot W, Quantin X, Boher JM, Andre F, Moreau L, Gainet M, et al; Association d’Enseignement et de Recherche des Internes en Oncologie. Brain metastases at the time of presentation of non-small cell lung cancer: a multi-centric AERIO analysis of prognostic factors. Br J Cancer 2001; 84: 903-9.
- 20. Cai Y, Wang JY, Liu H. Clinical observation of whole brain radiotherapy concomitant with targeted therapy for brain metastasis in non-small cell lung cancer patients with chemotherapy failure. Asian Pac J Cancer Prev 2013; 14: 5699-703.
- 21. Jin J, Zhou X, Liang X, Huang R, Chu Z, Jiang J, et al. Brain metastases as the first symptom of lung cancer: a clinical study from an Asian medical center. J Cancer Res Clin Oncol 2013; 139: 403-8.
- 22. Iuchi T, Shingyoji M, Sakaida T, Hatano K, Nagano O, Itakura M, et al. Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma. Lung Cancer 2013; 82: 282-7.
- 23. Shaw MG, Ball DL. Treatment of brain metastases in lung cancer: strategies to avoid/reduce late complications of whole brain radiation therapy. Curr Treat Options Oncol 2013; 14: 553-67.
- 24. Sakamoto J, Sonobe M, Kobayashi M, Ishikawa M, Kikuchi R, Nakajima D, et al. Prognostic factors for patients in postoperative brain metastases from surgically resected non-small cell lung cancer. Int J Clin Oncol 2014; 19: 50-6.
- 25. Inal A, Kodaz H, Odabas H, Duran AO, Seker MM, İnanc M, et al. Prognostic factors of patients who received chemotherapy after cranial irradiation for non-small cell lung cancer with brain metastases: A retrospective analysis of multicenter study (Anatolian Society of Medical Oncology). J Cancer Res Ther 2018; 14: 578-82.
- 26. Yu X, Fan Y. Real-World Data on Prognostic Factors for Overall Survival in EGFR-Mutant Non-Small-Cell Lung Cancer Patients with Brain Metastases. J Cancer 2019; 10: 3486-93.
- 27. Won YW, Joo J, Yun T, Lee GK, Han JY, Kim HT, et al. A nomogram to predict brain metastasis as the first relapse in curatively resected non-small cell lung cancer patients. Lung Cancer 2015; 88: 201‐7.
- 28. Smith DR, Bian Y, Wu CC, Saraf A, Tai CH, Nanda T, et al. Natural history, clinical course and predictors of interval time from initial diagnosis to development of subsequent NSCLC brain metastases. J Neurooncol 2019; 143: 145-55.
- 29. Viani GA, da Silva LG, Stefano EJ. Prognostic indexes for brain metastases: which is the most powerful? Int J Radiat Oncol Biol Phys 2012; 83: e325-30.
- 30. Kondziolka D, Parry PV, Lunsford LD, Kano H, Flickinger JC, Rakfal S, et al. The accuracy of predicting survival in individual patients with cancer. J Neurosurg 2014; 120: 24-30.
- 31. Harada H, Asakura H, Ogawa H, Mori K, Takahashi T, Nakasu Y, et al. Prognostic factors in patients with brain metastasis from non-small cell lung cancer treated with whole-brain radiotherapy. J Cancer Res Ther 2016; 12: 267-70.
| APA | Mermut Ö, Inanc B, Yardimci A (2021). Prediction of Prognostic Factors in the Survival of Non-smallcell Lung Cancer Patients with Multiple Brain Metastases. , 55 - 60. 10.4274/imj.galenos.2021.56650 |
| Chicago | Mermut Özlem,Inanc Berrin,Yardimci Aytul Hande Prediction of Prognostic Factors in the Survival of Non-smallcell Lung Cancer Patients with Multiple Brain Metastases. (2021): 55 - 60. 10.4274/imj.galenos.2021.56650 |
| MLA | Mermut Özlem,Inanc Berrin,Yardimci Aytul Hande Prediction of Prognostic Factors in the Survival of Non-smallcell Lung Cancer Patients with Multiple Brain Metastases. , 2021, ss.55 - 60. 10.4274/imj.galenos.2021.56650 |
| AMA | Mermut Ö,Inanc B,Yardimci A Prediction of Prognostic Factors in the Survival of Non-smallcell Lung Cancer Patients with Multiple Brain Metastases. . 2021; 55 - 60. 10.4274/imj.galenos.2021.56650 |
| Vancouver | Mermut Ö,Inanc B,Yardimci A Prediction of Prognostic Factors in the Survival of Non-smallcell Lung Cancer Patients with Multiple Brain Metastases. . 2021; 55 - 60. 10.4274/imj.galenos.2021.56650 |
| IEEE | Mermut Ö,Inanc B,Yardimci A "Prediction of Prognostic Factors in the Survival of Non-smallcell Lung Cancer Patients with Multiple Brain Metastases." , ss.55 - 60, 2021. 10.4274/imj.galenos.2021.56650 |
| ISNAD | Mermut, Özlem vd. "Prediction of Prognostic Factors in the Survival of Non-smallcell Lung Cancer Patients with Multiple Brain Metastases". (2021), 55-60. https://doi.org/10.4274/imj.galenos.2021.56650 |
| APA | Mermut Ö, Inanc B, Yardimci A (2021). Prediction of Prognostic Factors in the Survival of Non-smallcell Lung Cancer Patients with Multiple Brain Metastases. İstanbul Medical Journal, 22(1), 55 - 60. 10.4274/imj.galenos.2021.56650 |
| Chicago | Mermut Özlem,Inanc Berrin,Yardimci Aytul Hande Prediction of Prognostic Factors in the Survival of Non-smallcell Lung Cancer Patients with Multiple Brain Metastases. İstanbul Medical Journal 22, no.1 (2021): 55 - 60. 10.4274/imj.galenos.2021.56650 |
| MLA | Mermut Özlem,Inanc Berrin,Yardimci Aytul Hande Prediction of Prognostic Factors in the Survival of Non-smallcell Lung Cancer Patients with Multiple Brain Metastases. İstanbul Medical Journal, vol.22, no.1, 2021, ss.55 - 60. 10.4274/imj.galenos.2021.56650 |
| AMA | Mermut Ö,Inanc B,Yardimci A Prediction of Prognostic Factors in the Survival of Non-smallcell Lung Cancer Patients with Multiple Brain Metastases. İstanbul Medical Journal. 2021; 22(1): 55 - 60. 10.4274/imj.galenos.2021.56650 |
| Vancouver | Mermut Ö,Inanc B,Yardimci A Prediction of Prognostic Factors in the Survival of Non-smallcell Lung Cancer Patients with Multiple Brain Metastases. İstanbul Medical Journal. 2021; 22(1): 55 - 60. 10.4274/imj.galenos.2021.56650 |
| IEEE | Mermut Ö,Inanc B,Yardimci A "Prediction of Prognostic Factors in the Survival of Non-smallcell Lung Cancer Patients with Multiple Brain Metastases." İstanbul Medical Journal, 22, ss.55 - 60, 2021. 10.4274/imj.galenos.2021.56650 |
| ISNAD | Mermut, Özlem vd. "Prediction of Prognostic Factors in the Survival of Non-smallcell Lung Cancer Patients with Multiple Brain Metastases". İstanbul Medical Journal 22/1 (2021), 55-60. https://doi.org/10.4274/imj.galenos.2021.56650 |
